Investment analysts at Roth Capital assumed coverage on shares of Harpoon Therapeutics (NASDAQ:HARP) in a research note issued on Wednesday, TipRanks reports. The firm set a “buy” rating and a $25.00 price target on the stock. Roth Capital’s target price points to a potential upside of 85.05% from the stock’s previous close.
Other research analysts have also recently issued reports about the company. Zacks Investment Research cut Harpoon Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 9th. Canaccord Genuity cut their price objective on Harpoon Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Monday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Harpoon Therapeutics has a consensus rating of “Buy” and a consensus price target of $22.17.
Shares of NASDAQ HARP opened at $13.51 on Wednesday. The stock has a market cap of $319.81 million and a PE ratio of -0.53. The business has a fifty day moving average of $13.61 and a two-hundred day moving average of $13.09. Harpoon Therapeutics has a 52-week low of $9.07 and a 52-week high of $17.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.37 and a current ratio of 7.37.
Several institutional investors have recently added to or reduced their stakes in HARP. Tower Research Capital LLC TRC bought a new position in shares of Harpoon Therapeutics in the third quarter valued at about $26,000. Wells Fargo & Company MN bought a new position in shares of Harpoon Therapeutics in the second quarter valued at about $94,000. Northern Trust Corp raised its holdings in shares of Harpoon Therapeutics by 9.4% in the second quarter. Northern Trust Corp now owns 35,745 shares of the company’s stock valued at $465,000 after buying an additional 3,072 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Harpoon Therapeutics by 24.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 37,399 shares of the company’s stock valued at $487,000 after buying an additional 7,232 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Harpoon Therapeutics by 183.3% in the second quarter. Vanguard Group Inc. now owns 234,377 shares of the company’s stock valued at $3,047,000 after buying an additional 151,644 shares during the last quarter. 56.45% of the stock is owned by institutional investors and hedge funds.
About Harpoon Therapeutics
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.